Blair William & Co. IL Reduces Stake in Merck & Co., Inc.

Institutional investor lowers position in pharmaceutical giant

Published on Mar. 8, 2026

Got story updates? Submit your updates here. ›

According to a recent SEC filing, Blair William & Co. IL lowered its stake in shares of Merck & Co., Inc. (NYSE:MRK) by 6.9% in the third quarter. The fund now owns 812,366 shares of the company's stock, valued at $68,182,000.

Why it matters

Merck is a major pharmaceutical company with a diverse portfolio of drugs and vaccines. Changes in institutional ownership of the stock can provide insights into market sentiment and potential future performance.

The details

Blair William & Co. IL sold 60,101 shares of Merck & Co., Inc. during the third quarter, reducing its total position to 812,366 shares. The firm cited unspecified reasons for the stock sale, which represented a 6.9% decrease in its overall stake in the company.

  • The stock sale occurred during the third quarter of 2026.

The players

Blair William & Co. IL

An institutional investment management firm that owns shares in Merck & Co., Inc.

Merck & Co., Inc.

A global biopharmaceutical company that develops and markets prescription medicines, vaccines, biologic therapies, and animal health products.

Got photos? Submit your photos here. ›

The takeaway

The reduction in Blair William & Co. IL's position in Merck & Co., Inc. may signal a shift in institutional sentiment towards the pharmaceutical company, though the specific reasons behind the sale are unclear. Investors will likely continue to monitor changes in major shareholders' holdings of Merck stock.